According to the World Health Organization (WHO), undesirable effects are classified according to their rate of development as follows: very common (> 1/10), common (> 1/100, <1/10), uncommon (> 1/1000, <1/100) rarely (> 1/10000, <1/1000) and very rarely (<1/10000); frequency is unknown (the frequency of occurrence of phenomena can not be determined on the basis of available data).
From the side of the immune system the frequency is unknown: angioedema (Quincke's edema).
From the cardiovascular system often: moderate bradycardia (dose-dependent); infrequently: sinoatrial and AV blockade of various degrees, proarrhythmic action up to sinus arrest (the emergence of new or aggravation of existing arrhythmias, including with cardiac arrest), in some cases asystole was observed; very rare bradycardia, stopping the sinus node (in patients with sinus node dysfunction and elderly patients), progression of chronic heart failure (with prolonged use), ventricular fibrillation / flutter; frequency unknown: ventricular tachycardia of the "pirouette" type.
From the side of the digestive system very often: nausea, vomiting, loss of appetite, dullness or loss of taste, dysgeusia (metallic taste in the mouth),feeling of heaviness in the epigastrium, increased activity of an isolated "liver" enzymes (1,5-3 times higher than normal), usually moderate and reduces in dose reduction or even spontaneously; often: Acute toxic hepatitis with increased activity of "liver" transaminases and / or jaundice, including development of hepatic insufficiency, incl. with lethal outcome; very rarely: chronic hepatic insufficiency (pseudo-alcoholic hepatitis, cirrhosis), incl. with a lethal outcome, pancreatitis.
On the part of the respiratory system often: interstitial or alveolar pneumonitis, allergic pneumonitis, bronchiolitis obliterans with pneumonia, incl. with a lethal outcome, pleurisy, pulmonary fibrosis; very rarely: bronchospasm in patients with severe respiratory failure (especially in patients with bronchial asthma), acute respiratory syndrome (distress syndrome), incl. with lethal outcome; pulmonary hemorrhage.
From the senses very often: microcalcifications in the corneal epithelium, consisting of complex lipids, including lipofuscin (complaints on color appearance of ghosting or fuzziness of contours of objects in bright light), scotoma, macular degeneration, photosensitivity and degeneration of the cornea; rarely: optic neuritis / visual neuropathy.
From the side of metabolism often: hypothyroidism, hyperthyroidism; very rarely: syndrome of impaired secretion of antidiuretic hormone.
On the part of the skin is very often: photosensitivity; often: grayish or bluish skin pigmentation (with prolonged use, disappears after discontinuation of the drug); very rarely: erythema (with simultaneous radiotherapy), skin rash, exfoliative dermatitis (there is no connection with taking the drug), erythema multiforme and Stevens-Johnson syndrome, alopecia; frequency unknown: hives.
From the side of the central nervous system often: tremor and other extrapyramidal symptoms, sleep disturbances, incl. "nightmarish" dreams; infrequent: peripheral neuropathy (sensorimotor, motor, mixed) and / or myopathy, usually reversible after drug withdrawal, dizziness; very rarely: cerebellar ataxia, benign intracranial hypertension (pseudotumour of the brain), headache. On the part of the blood and lymphatic system very rarely: thrombocytopenia, hemolytic or aplastic anemia, neutropenia, pancytopenia.Other often: weakness in the muscles; very rarely: peripheral edema, anaphylactic shock, epididymitis, impotence (connection with the drug is not established), myopathy, vasculitis, an increase in the concentration of creatinine in the blood plasma; frequency unknown: bone marrow granuloma.